The Rise and Challenges of BioNTech: From COVID-19 Success to New Horizons and Workforce Transformations
BioNTech's mRNA vaccine success transitions to a new chapter focusing on cancer therapies. The company reported a decline in earnings per share to 1.08 euros but beat market expectations. Revenue…